Almac Group Recognised as a Top 50 Company for Transatlantic Operations
June 19, 2017
Souderton, US, June 19, 2017– Almac Group, the global contract pharmaceutical development and manufacturing organisation, is delighted to have received recognition as a US-Ireland Top 50 Company for its commitment to building prosperity through business and job creation.
The Irish Echo Newspaper’s 10th Annual Awards Luncheon highlights companies who exhibit dedication to strengthening international trade between the US and Northern Ireland. The luncheon emphasises a commitment to future progress and prosperity between the citizens of New York, NY, US and Belfast, Northern Ireland, UK, while celebrating a shared history and past.
Almac received the award by demonstrating long-term growth by expanding venture in its US and Northern Ireland operations and investing more than $56 million combined, which will create more than 700 full-time jobs. As a result of this investment, Almac’s global headcount will increase to over 5,000 by the end of 2017. These expansions are supported by the Office of International Business Development, Pennsylvania Department of Community & Economic Development, and the Department of Jobs, Enterprise and Innovation through IDA Ireland, The Republic of Ireland’s inward investment promotion agency.
Mark Weir, US Group Financial Controller, commented: “At a time when our commitment to expanding operations in the US and Northern Ireland is strong, we are delighted to receive recognition as a US-Ireland Top 50 Company. By broadening performance and job opportunities, Almac is dedicated to mutual growth. Our company’s history is shaped by relationships and they remain fundamental to Almac’s future.”
This worldwide recognition showcases Almac’s mission in ‘partnering to advance human health’ by making continued investments into the communities it serves. Almac understands its advantage by offering industry-leading products and services to broaden the Group’s impact in the US, Northern Ireland, and worldwide.
To find out more about this award and request a meeting or information e-mail [email protected]
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown almost 50 years and now employs in excess of 5600 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).